-
Gemphire Flirts With $1 Level As Struggling Biotech Strikes Reverse Merger Deal
Thursday, July 25, 2019 - 10:15am | 530Read More...Gemphire Therapeutics Inc (NASDAQ: GEMP) stock — which has been on a broader downtrend since mid-2017 — was advancing strongly Thursday. The stock has been under pressure amid some clinical trial setbacks, and has been trading in penny stock territory since late May. The...
-
Gemphire Therapeutics Could Have A Blockbuster Drug In Development
Tuesday, September 6, 2016 - 11:38am | 378Read More...Laidlaw’s Jim Molloy believes Gemphire Therapeutics Inc’s (NASDAQ: GEMP) lead product candidate, Gemcabene, has the potential to become one of the most interesting entrants to the cardiovascular disease (CVD) space, with “true blockbuster potential.” Molloy initiated...
-
Gemphire Therapeutics' Oral Cholesterol Drug Could Have $2.8 Billion Potential In U.S. Market
Tuesday, August 30, 2016 - 1:23pm | 333Read More...Canaccord Genuity said Gemphire Therapeutics Inc (NASDAQ: GEMP)'s oral cholesterol drug Gemcabene has a peak U.S. market potential of $2.8 billion. The firm initiated coverage of the stock with a Buy rating. The brokerage also set a price target of $17, implying a potential upside of 67 percent...
